{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:46:50Z","timestamp":1790221610209,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574373"],"award-info":[{"award-number":["82574373"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104133"],"award-info":[{"award-number":["82104133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40259-026-00775-z","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:55:28Z","timestamp":1775188528000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Benefit and Global Regulation of Bispecific Antibody Drugs: A Cross-sectional Analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Renjie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4396-3870","authenticated-orcid":false,"given":"Yafang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"4","key":"775_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"775_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"775_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2321635","volume":"16","author":"M Surowka","year":"2024","unstructured":"Surowka M, Klein C. A pivotal decade for bispecific antibodies? MAbs. 2024;16(1):2321635. https:\/\/doi.org\/10.1080\/19420862.2024.2321635.","journal-title":"MAbs"},{"issue":"9","key":"775_CR4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding A, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1609783.","journal-title":"N Engl J Med"},{"issue":"4","key":"775_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320\u201333. https:\/\/doi.org\/10.1056\/NEJMoa2312948.","journal-title":"N Engl J Med"},{"issue":"5","key":"775_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","volume":"57","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Bargou R. Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma. 2016;57(5):1021\u201332. https:\/\/doi.org\/10.3109\/10428194.2016.1161185.","journal-title":"Leuk Lymphoma"},{"key":"775_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00185-w","author":"S Crescioli","year":"2025","unstructured":"Crescioli S, Reichert JM. Innovative antibody therapeutic development in China compared with the USA and Europe. Nat Rev Drug Discov. 2025. https:\/\/doi.org\/10.1038\/d41573-025-00185-w.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"775_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11899-024-00748-5","volume":"20","author":"PR Keesari","year":"2025","unstructured":"Keesari PR, Samuels D, Vegivinti CTR, Pulakurthi YS, Kudithi R, Dhar M, et al. Navigating the economic burden of multiple myeloma: insights into cost-effectiveness of CAR-T and bispecific antibody therapies. Curr Hematol Malig Rep. 2025;20(1):3. https:\/\/doi.org\/10.1007\/s11899-024-00748-5.","journal-title":"Curr Hematol Malig Rep"},{"key":"775_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393939","volume":"15","author":"OO Oluwole","year":"2024","unstructured":"Oluwole OO, Ray MD, Zur RM, Ferrufino CP, Doble B, Patel AR, et al. Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States. Front Immunol. 2024;15:1393939. https:\/\/doi.org\/10.3389\/fimmu.2024.1393939.","journal-title":"Front Immunol"},{"issue":"7","key":"775_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","volume":"179","author":"EY Chen","year":"2019","unstructured":"Chen EY, Raghunathan V, Prasad V. An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate. JAMA Intern Med. 2019;179(7):915\u201321. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0583.","journal-title":"JAMA Intern Med"},{"issue":"17","key":"775_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","volume":"331","author":"ITT Liu","year":"2024","unstructured":"Liu ITT, Kesselheim AS, Cliff ERS. Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval. JAMA. 2024;331(17):1471\u20139. https:\/\/doi.org\/10.1001\/jama.2024.2396.","journal-title":"JAMA"},{"issue":"3","key":"775_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s13311-020-00906-6","volume":"17","author":"COS Clair","year":"2020","unstructured":"Clair COS, Papadopoulos EJ. Considerations in the assessment of clinical benefit with a focus on pain: a regulatory perspective. Neurotherapeutics. 2020;17(3):770\u20133. https:\/\/doi.org\/10.1007\/s13311-020-00906-6.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"775_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jviscsurg.2013.10.001","volume":"151","author":"F Fiteni","year":"2014","unstructured":"Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetain F. Endpoints in cancer clinical trials. J Visc Surg. 2014;151(1):17\u201322. https:\/\/doi.org\/10.1016\/j.jviscsurg.2013.10.001.","journal-title":"J Visc Surg"},{"issue":"35","key":"775_CR14","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/jco.22.00535","volume":"40","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Michaeli T. Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021. J Clin Oncol. 2022;40(35):4095\u2013106. https:\/\/doi.org\/10.1200\/jco.22.00535.","journal-title":"J Clin Oncol"},{"key":"775_CR15","unstructured":"US Food and Drug Administration (FDA). Drugs@FDA: FDA approved drug products. Available at https:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/. Accessed 29 Jan 2025."},{"key":"775_CR16","unstructured":"European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/ Accessed 29 May 2025."},{"key":"775_CR17","unstructured":"Center for drug evaluation, Chinese National Medical Products Administration (NMPA). https:\/\/www.cde.org.cn\/ Accessed 29 May 2025."},{"key":"775_CR18","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). https:\/\/www.pmda.go.jp\/ Accessed 29 May 2025."},{"key":"775_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2815","volume":"362","author":"A Ladanie","year":"2018","unstructured":"Ladanie A, Ewald H, Kasenda B, Hemkens LG. How to use FDA drug approval documents for evidence syntheses. BMJ. 2018;362:k2815. https:\/\/doi.org\/10.1136\/bmj.k2815.","journal-title":"BMJ"},{"key":"775_CR20","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/s0959-8049(01)00448-8","volume":"Suppl 4","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A, EORTC Quality of Life Group, Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. Eur J Cancer. 2002;Suppl 4:S125-133. https:\/\/doi.org\/10.1016\/s0959-8049(01)00448-8.","journal-title":"Eur J Cancer"},{"issue":"5","key":"775_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"key":"775_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102824","volume":"76","author":"A Mittal","year":"2024","unstructured":"Mittal A, Kim MS, Dunn S, Wright K, Gyawali B. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward. EClinicalMedicine. 2024;76:102824. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102824.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"775_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","volume":"14","author":"A Santoro","year":"2013","unstructured":"Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Laethem JLV, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(12)70490-4.","journal-title":"Lancet Oncol"},{"key":"775_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","volume":"19","author":"L Rimassa","year":"2018","unstructured":"Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19:682\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30146-3.","journal-title":"Lancet Oncol"},{"issue":"13","key":"775_CR25","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2020.1707","volume":"323","author":"WD Tap","year":"2020","unstructured":"Tap WD, Wagner AJ, Sch\u00f6ffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas. JAMA. 2020;323(13):1266\u201376. https:\/\/doi.org\/10.1001\/jama.2020.1707.","journal-title":"JAMA"},{"issue":"10043","key":"775_CR26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","volume":"388","author":"WD Tap","year":"2016","unstructured":"Tap WD, Jones RL, Tine BAV, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(16)30587-6.","journal-title":"Lancet"},{"issue":"16","key":"775_CR27","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1001\/archinternmed.2011.396","volume":"171","author":"LM Schwartz","year":"2011","unstructured":"Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public: a national randomized trial. Arch Intern Med. 2011;171(16):1463\u20138. https:\/\/doi.org\/10.1001\/archinternmed.2011.396.","journal-title":"Arch Intern Med"},{"issue":"1","key":"775_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.117.","journal-title":"Ann Oncol"},{"issue":"10","key":"775_CR29","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","volume":"29","author":"BC Cho","year":"2023","unstructured":"Cho BC, Kim DW, Spira AI, Gomez JE, Haura EB, Kim SW, et al. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nat Med. 2023;29(10):2577\u201385. https:\/\/doi.org\/10.1038\/s41591-023-02554-7.","journal-title":"Nat Med"},{"issue":"26","key":"775_CR30","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","volume":"131","author":"MS Topp","year":"2018","unstructured":"Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A, et al. Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 2018;131(26):2906\u201314. https:\/\/doi.org\/10.1182\/blood-2017-09-804658.","journal-title":"Blood"},{"issue":"13","key":"775_CR31","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"issue":"11","key":"775_CR32","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/art.42273","volume":"74","author":"T Takeuchi","year":"2022","unstructured":"Takeuchi T, Kawanishi M, Nakanishi M, Yamasaki H, Tanaka Y. Phase II\/III results of a trial of anti-tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis. Arthritis Rheumatol. 2022;74(11):1776\u201385. https:\/\/doi.org\/10.1002\/art.42273.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"775_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med. 2018;379(9):811\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1803550.","journal-title":"N Engl J Med"},{"issue":"9","key":"775_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017;377(9):809\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1703068.","journal-title":"N Engl J Med"},{"key":"775_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101483","volume":"55","author":"X Mao","year":"2025","unstructured":"Mao X, Xu J, Liu X, Kong S, Li Y, Bai X, et al. Regulatory flexibilities balancing unmet needs, benefits and risks in the approvals of imported cancer drugs in China: a cohort study from 2012 to 2021. Lancet Reg Health West Pac. 2025;55:101483. https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101483.","journal-title":"Lancet Reg Health West Pac."},{"issue":"1","key":"775_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.4750","volume":"6","author":"Y Wei","year":"2025","unstructured":"Wei Y, Zhang Y, Li H, Shi L, Guan X. Expedited approval of urgently needed drugs in China. JAMA Health Forum. 2025;6(1):e244750. https:\/\/doi.org\/10.1001\/jamahealthforum.2024.4750.","journal-title":"JAMA Health Forum."},{"issue":"15","key":"775_CR37","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3390\/ijms20153801","volume":"20","author":"S Nagai","year":"2019","unstructured":"Nagai S. Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan. Int J Mol Sci. 2019;20(15):3801. https:\/\/doi.org\/10.3390\/ijms20153801.","journal-title":"Int J Mol Sci"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00775-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:45:50Z","timestamp":1779795950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00775-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"22 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data relevant to the study are included in the article or uploaded as electronic supplementary materials. All analyzed summary data were extracted from publicly available sources.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All analyzed summary data were extracted from publicly available sources. Ethical approval is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The code used in this study is available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"YH designed the study. RW and TZ collected the data. YH, RW, and TZ accessed and verified the data. YH, RW, and TZ analyzed the data. All authors were responsible for the decision to submit the manuscript. All authors contributed to the analysis and interpreted the results. YH drafted the initial manuscript. All authors revised the manuscript critically for intellectual content and gave final approval.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}